Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2017 May;15(5):619-630. doi: 10.1016/j.cgh.2016.10.021. Epub 2016 Oct 28.

Endoscopic Bariatric and Metabolic Therapies: Surgical Analogues and Mechanisms of Action.

Author information

1
Division of Gastroenterology, Hepatology and Endoscopy, Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
2
Division of Gastroenterology, Hepatology and Endoscopy, Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: ccthompson@bwh.harvard.edu.

Abstract

Obesity is a worsening pandemic with numerous related comorbid illnesses. Conservative management including lifestyle modification and medications have limited efficacy. In contradistinction, bariatric surgery is effective, however, with substantial cost and non-negligible morbidity and mortality. As such, a small percentage of eligible patients undergo surgery. Over the past decade, endoscopic bariatric and metabolic therapies have been introduced as a less invasive option for the treatment of obesity and its related comorbid illnesses. This article reviews major endoscopic bariatric and metabolic therapies, their surgical analogues, and proposed mechanisms of action. Clinical trial data for each device also are discussed.

KEYWORDS:

Aspire; Bariatric; Diabetes; Duo; EBMT; EBT; ESG; EndoBarrier; Endoscopic Sleeve Gastroplasty; Endoscopy; GLP-1; Gastric Balloon; Ghrelin; IMAS; Incretin; Magnetic; Metabolic; Obalon; Obesity; Orbera; POSE; PYY

PMID:
27989851
PMCID:
PMC5444453
DOI:
10.1016/j.cgh.2016.10.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center